Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jennie Ilomaki"'
Autor:
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri, Jonathan E Shaw, Jenni Ilomäki, Avraham Karasik, Su-Yen Goh, Chern-En Chiang, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, Mikhail Kosiborod, John P Wilding, Kamlesh Khunti, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Luis Alberto García Rodríguez, Jonathan Shaw, Suzanne Arnold, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer-Cohen, Reid Whitlock, Lucia Cea-Soriano, Oscar Fernándex Cantero, Jordan A. Menzin, Matthew Guthrie, Jennie Ilomaki, Dianna Magliano
Publikováno v:
Kohsaka, S, Lam, C S P, Kim, D J, Cavender, M A, Norhammar, A, Jørgensen, M E, Birkeland, K, Holl, R W, Franch-Nadal, J, Tangri, N, Shaw, J, Ilomäki, J, Karasik, A, Goh, S Y, Chiang, C E, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P & Kosiborod, M 2020, ' Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors : an analysis from the CVD-REAL 2 multinational cohort study ', The Lancet Diabetes and Endocrinology, vol. 8, no. 7, pp. 606-615 . https://doi.org/10.1016/S2213-8587(20)30130-3
Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC
Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC
Background: Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed
Autor:
Mikhail Kosiborod, Carolyn S.P. Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen, Filip Surmont, Niklas Hammar, Peter Fenici, Matthew A. Cavender, Alex Z. Fu, John P. Wilding, Kamlesh Khunti, Anna Norhammar, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Josep Franch-Nadal, Luis Alberto García Rodríguez, Suzanne Arnold, Johan Bodegård, Kyle Nahrebne, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer Cohen, Reid Whitlock, Lucia Cea Soriano, Oscar Fernándex Cantero, Ellen Riehle, Jennie Ilomaki, Dianna Magliano
Publikováno v:
Journal of the American College of Cardiology. 71:2628-2639
Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high...